Skip to main content

Table 3 Summary of estimated cases, non-discounted and discounted total costs and life-years of a single age-cohort (n = 25,000) of 12 year old girls

From: Cost-effectiveness of different human papillomavirus vaccines in Singapore

   Screening only Bivalent* Quadrivalent*
Cases     
  Cervical cancer 229 32 53
  Deaths from cervical cancer 144 20 33
  CIN Persistent 2n3 detected 2,073 294 480
  CIN 2n3 detected 382 135 168
  CIN 1 detected 2,109 1,127 1,293
  Genital warts 4,126 4,126 447
NON-DISCOUNTED     
Total costs   21,150,496 25,020,340 22,822,396
  Vaccine costs - 10,000,000 10,000,000
  Screening costs 11,006,014 9,949,324 10,078,234
  CIN1 treatment costs 2,330,522 1,245,203 1,292,796
  CIN 2 & 3 treatment costs 564,776 199,475 247,908
  CIN Persistent 2 & 3 treatment costs 3,067,301 435,141 710,367
  Genital warts treatment costs 3,094,714 3,094,714 335,580
  Cervical cancer treatment costs 1,087,169 96,483 157,511
Life-years (LY)   1,692,651 1,695,651 1,695,338
QALYs   1,717,089 1,720,571 1,720,299
DISCOUNTED     
Total costs   6,880,106 15,034,926 14,210,399
Life-years (LY)   711,164 711,800 711,734
QALYs   735,991 736,775 736,784
  1. *In addition to screening